Hypersensitivity reactions, cumulative fluid retention, and neurotoxicity are frequently seen toxicities related to docetaxel. Fluid retention may be present as edema, weight gain, or third place fluid collection. Pericardial effusion is rarely seen with docetaxel treatment. We report a 58-year-old female patient who was presented with pericardial tamponade after three cycles of docetaxel therapy.
Abu-KhalafMMHarrisLNAntimicrotubule agents. In: DeVitaVTLawrenceTSRosenbergSA (eds). Cancer principles & practice of oncology20119th ed. Philadelphia, PA, USA: Lippincott Williams & Wilkins, pp. 413–421.
2.
BurrisHIrvinRKuhnJ. Phase I clinical trial of taxotere administered as either a 2-hour or 6-hour intravenous infusion. J Clin Oncol1993; 11: 950–958.
3.
FossellaFVLeeJSMurphyWK. Phase II study of docetaxel for recurrent or metastatic non-small-cell lung cancer. J Clin Oncol1994; 12: 1238–1244.
4.
PoiMJBergerMLustbergM. Docetaxel-induced skin toxicities in breast cancer patients subsequent to paclitaxel shortage: a case series and literature review. Support Care Cancer2013; 21: 2679–2686.
5.
TomiakEPiccartMJKergerJ. Phase I study of docetaxel administered as 1-hour intravenous infusion on a weekly basis. J Clin Oncol1994; 12: 1458–1467.
6.
SembKAAamdalSOianP. Capillary protein leak syndrome appears to explain fluid retention in cancer patients who receive docetaxel treatment. J Clin Oncol1998; 16: 3426–3432.
ChevallierBFumoleauPKerbratP. Docetaxel is a major cytotoxic drug for the treatment of advanced breast cancer: a phase II trial of the clinical screening cooperative group of the European organization for research and treatment of cancer. J Clin Oncol1995; 13: 314–322.
